A phase 3, randomized, open-label, multicenter, global study of Durvalumab and bacillus calmette-Guerin (BCG) vs BCG alone in high-risk, BCG-naive non-muscle-invasive bladder cancer (NMIBC) patients (POTOMAC)
ONCOLOGY RESEARCH AND TREATMENT（2019）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined